标题
Can EGFR be a therapeutic target in breast cancer?
作者
关键词
-
出版物
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Volume 1877, Issue 5, Pages 188789
出版商
Elsevier BV
发表日期
2022-09-03
DOI
10.1016/j.bbcan.2022.188789
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phosphorylation of PKCδ by FER tips the balance from EGFR degradation to recycling
- (2021) Ana Lonic et al. JOURNAL OF CELL BIOLOGY
- LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
- (2021) Green Ahn et al. Nature Chemical Biology
- Faciogenital Dysplasia 5 supports cancer stem cell traits in basal-like breast cancer by enhancing EGFR stability
- (2021) Ke Li et al. Science Translational Medicine
- Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition
- (2021) Lin Xia et al. Cancer Immunology Research
- GABRP sustains the stemness of triple-negative breast cancer cells through EGFR signaling
- (2021) Xiyin Li et al. CANCER LETTERS
- A Wnt-Independent LGR4–EGFR Signaling Axis in Cancer Metastasis
- (2021) Fei Yue et al. CANCER RESEARCH
- Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors
- (2020) Dima A. Sabbah et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)
- (2020) Hao Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- EGFR Promotes the Development of Triple Negative Breast Cancer Through JAK/STAT3 Signaling
- (2020) Xiang Song et al. Cancer Management and Research
- Design and synthesis of selective degraders of EGFRL858R/T790M mutant
- (2020) Xin Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
- (2020) Xin Li et al. Journal of Hematology & Oncology
- Emerging New Concepts of Degrader Technologies
- (2020) Yu Ding et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Targeting epidermal growth factor‐overexpressing triple‐negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor
- (2020) Yan Liu et al. CELL PROLIFERATION
- Lysosome-targeting chimaeras for degradation of extracellular proteins
- (2020) Steven M. Banik et al. NATURE
- The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer
- (2020) Hui Liu et al. Cancer Discovery
- SGCE Promotes Breast Cancer Stem Cells by Stabilizing EGFR
- (2020) Lina Zhao et al. Advanced Science
- RAB31 marks and controls an ESCRT-independent exosome pathway
- (2020) Denghui Wei et al. CELL RESEARCH
- Discovery of potent small molecule PROTACs targeting mutant EGFR
- (2020) Hong-Yi Zhao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation
- (2019) Meiyang Xi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years
- (2019) Tino F. Schwarz et al. Human Vaccines & Immunotherapeutics
- Targeting of early endosomes by autophagy facilitates EGFR recycling and signalling
- (2019) Jane Fraser et al. EMBO REPORTS
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Locked nucleic acid: modality, diversity, and drug discovery
- (2018) Peter H. Hagedorn et al. DRUG DISCOVERY TODAY
- HRS–WASH axis governs actin-mediated endosomal recycling and cell invasion
- (2018) Ewan MacDonald et al. JOURNAL OF CELL BIOLOGY
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
- (2018) Chong Qin et al. JOURNAL OF MEDICINAL CHEMISTRY
- EGFR-TKIs resistance via EGFR-independent signaling pathways
- (2018) Qian Liu et al. Molecular Cancer
- Targeted delivery of CD44s-siRNA by ScFv overcomes de novo resistance to cetuximab in triple negative breast cancer
- (2018) Wenyan Fu et al. MOLECULAR IMMUNOLOGY
- TGF-β transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK/Sp1 signaling pathways
- (2018) Yuanyuan Zhao et al. Molecular Oncology
- Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
- (2018) Eugenio Mercuri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies
- (2018) Zhenyi An et al. ONCOGENE
- Personalized vaccines for cancer immunotherapy
- (2018) Ugur Sahin et al. SCIENCE
- Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine
- (2018) Ellen Wargowski et al. Journal for ImmunoTherapy of Cancer
- Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3
- (2018) Hester A. Doyle et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Lapatinib induced Annexin A6 up-regulation as an adaptive response of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors
- (2018) Sarrah E Widatalla et al. CARCINOGENESIS
- GPR119 agonist enhances gefitinib responsiveness through lactate-mediated inhibition of autophagy
- (2018) Ji Hye Im et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression
- (2018) Yangbing Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs
- (2017) Kanakaraju Manupati et al. FEBS Journal
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells
- (2017) Katsuya Nakai et al. Breast Cancer
- A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer
- (2017) Paul Savage et al. Cell Reports
- Autophagy inhibitor facilitates gefitinib sensitivity in vitro and in vivo by activating mitochondrial apoptosis in triple negative breast cancer
- (2017) Zhaoyun Liu et al. PLoS One
- Determinants of resistance to chemotherapy and ionizing radiation in breast cancer stem cells
- (2016) Athanasia Pavlopoulou et al. CANCER LETTERS
- 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
- (2016) Luca Gianni et al. LANCET ONCOLOGY
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phosphatidic Acid (PA) conveyor system of continuous intracellular transport from cell membrane to nucleus maintains EGF receptor homeostasis
- (2016) Karen M. Henkels et al. Oncotarget
- Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT–mTOR pathway
- (2015) Miao Deng et al. ANTI-CANCER DRUGS
- High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers
- (2015) William Jacot et al. BMC CANCER
- The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis
- (2015) Lisa M. Ooms et al. CANCER CELL
- Kindlin-2 interacts with and stabilizes EGFR and is required for EGF-induced breast cancer cell migration
- (2015) Baohui Guo et al. CANCER LETTERS
- Ligand-Independent EGFR Signaling
- (2015) G. Guo et al. CANCER RESEARCH
- A Kinase-Independent Role for EGF Receptor in Autophagy Initiation
- (2015) Xiaojun Tan et al. CELL
- Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells
- (2015) Mariana Segovia-Mendoza et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
- (2015) Lecia V. Sequist et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma
- (2015) Laura A. Johnson et al. Science Translational Medicine
- Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas
- (2015) Kui Wu et al. Nature Communications
- Immunohistochemical Localization of Wild-type EGFR, E746-A750 Frame Deletion in Exon 19, and L858R Point Mutation in Exon 21 in Triple-negative Breast Cancer
- (2015) Hemangini H. Vora et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Trial Watch: Peptide-based anticancer vaccines
- (2015) Jonathan Pol et al. OncoImmunology
- CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
- (2015) Jianfeng Han et al. Scientific Reports
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
- (2014) Mark G. Kris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- High EGFR gene copy number predicts poor outcome in triple-negative breast cancer
- (2014) Heae Surng Park et al. MODERN PATHOLOGY
- Oncogenic signaling in amphiregulin and EGFR-expressing PTEN-null human breast cancer
- (2014) Christiana S. Kappler et al. Molecular Oncology
- The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility
- (2014) T. Kiuchi et al. Science Signaling
- The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases
- (2014) M. A. Lemmon et al. Cold Spring Harbor Perspectives in Biology
- Dual inhibition of EGFR at protein and activity level via combinatorial blocking of PI4KIIα as anti-tumor strategy
- (2014) Jiangmei Li et al. Protein & Cell
- Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors
- (2013) Kazuto Furuyama et al. CANCER SCIENCE
- P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency
- (2013) Iuliana Shapira et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
- (2013) Raul D. Santos et al. EUROPEAN HEART JOURNAL
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Metastasis Suppressor Tetraspanin CD82/KAI1 Regulates Ubiquitylation of Epidermal Growth Factor Receptor
- (2013) Elena Odintsova et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- High expression of LC3B is associated with progression and poor outcome in triple-negative breast cancer
- (2013) Hong Zhao et al. MEDICAL ONCOLOGY
- Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors
- (2013) Rainelli B Koumangoye et al. Molecular Cancer
- The quest to overcome resistance to EGFR-targeted therapies in cancer
- (2013) Curtis R Chong et al. NATURE MEDICINE
- Induction of Autophagy Is an Early Response to Gefitinib and a Potential Therapeutic Target in Breast Cancer
- (2013) Wieslawa H. Dragowska et al. PLoS One
- Endocytosis of Receptor Tyrosine Kinases
- (2013) L. K. Goh et al. Cold Spring Harbor Perspectives in Biology
- Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer
- (2012) Tobias J. Grob et al. BREAST CANCER RESEARCH AND TREATMENT
- Epidermal Growth Factor Receptor Variant III Contributes to Cancer Stem Cell Phenotypes in Invasive Breast Carcinoma
- (2012) C. A. Del Vecchio et al. CANCER RESEARCH
- Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
- (2012) Yibing Shan et al. CELL
- A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells
- (2012) Courtney R. Giordano et al. EXPERIMENTAL CELL RESEARCH
- Exon 8 amplification of epidermal growth factor receptor (EGFR) in invasive breast carcinomas
- (2012) Efthimia Souka et al. HISTOPATHOLOGY
- Expression of autophagy-related markers beclin-1, light chain 3A, light chain 3B and p62 according to the molecular subtype of breast cancer
- (2012) Junjeong Choi et al. HISTOPATHOLOGY
- Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma
- (2012) B. D. Choi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Suppression of EGFR endocytosis by dynamin depletion reveals that EGFR signaling occurs primarily at the plasma membrane
- (2012) L. P. Sousa et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer
- (2012) Hiroki Nakajima et al. Breast Cancer
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial
- (2011) Mogens Bernsdorf et al. BREAST CANCER RESEARCH AND TREATMENT
- Regulation of the catalytic activity of the EGF receptor
- (2011) Nicholas F Endres et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations
- (2011) Ning Lv et al. Diagnostic Pathology
- Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
- (2011) Hiromichi Ebi et al. JOURNAL OF CLINICAL INVESTIGATION
- Incidence ofEGFRExon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas
- (2011) Sandra P. D'Angelo et al. JOURNAL OF CLINICAL ONCOLOGY
- TIEG1 Inhibits Breast Cancer Invasion and Metastasis by Inhibition of Epidermal Growth Factor Receptor (EGFR) Transcription and the EGFR Signaling Pathway
- (2011) W. Jin et al. MOLECULAR AND CELLULAR BIOLOGY
- Feedback regulation of EGFR signalling: decision making by early and delayed loops
- (2011) Roi Avraham et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- LC3A-Positive Light Microscopy Detected Patterns of Autophagy and Prognosis in Operable Breast Carcinomas
- (2010) Efthimios Sivridis et al. AMERICAN JOURNAL OF PATHOLOGY
- Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer
- (2010) Alfonso Sánchez-Muñoz et al. BMC CANCER
- Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF-induced a transient effect on EGFR-mediated signaling pathways
- (2010) Hong Yu et al. CANCER BIOLOGY & THERAPY
- Identification of the Switch in Early-to-Late Endosome Transition
- (2010) Dmitry Poteryaev et al. CELL
- Personalized medicine for non-small-cell lung cancer
- (2010) Tony S Mok et al. Expert Review of Anticancer Therapy
- Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib
- (2010) Mary E. Irwin et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers
- (2010) C. G. Fedele et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer
- (2009) M. D. Green et al. ANNALS OF ONCOLOGY
- Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
- (2009) B. Neyns et al. ANNALS OF ONCOLOGY
- Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer
- (2009) Michael J. Eck et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance
- (2009) J. Nevo et al. CLINICAL CANCER RESEARCH
- In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
- (2009) K. P. Hoeflich et al. CLINICAL CANCER RESEARCH
- Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy
- (2009) W.-X. Ding et al. MOLECULAR CANCER THERAPEUTICS
- Autophagy in tumour suppression and promotion
- (2009) Andreas Brech et al. Molecular Oncology
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- (2009) Rafael Rosell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3
- (2009) N. Jura et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
- (2009) C. J. Creighton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers
- (2008) Tatsuya Toyama et al. BMC CANCER
- Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity
- (2008) Giuseppe Viale et al. BREAST CANCER RESEARCH AND TREATMENT
- Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop
- (2008) Nicole E. Willmarth et al. CELLULAR SIGNALLING
- Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
- (2008) X. Li et al. JNCI-Journal of the National Cancer Institute
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis
- (2007) Kirsteen H. Maclean et al. JOURNAL OF CLINICAL INVESTIGATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started